Active stumbles; Peptide takes notes

Active Biotech AB thought it had found a suitable group of patients in its Phase II trials who would respond to its ETEC vaccine to treat enterotoxigenic E. coli-associated diarrhea in travelers. But following last week's failure of its Phase III trial, the company plans to pore through the

Read the full 498 word article

How to gain access

Continue reading with a
two-week free trial.